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effectiveness in the prevention of pneumonia due to influenza in the Colombian 
children and elderly population. METHODS: A probabilistic decision-tree model to 
simulate Influenza-Like Syndrome (ILS) burden of disease and influenza pneumo-
nia complications in Colombian population was programmed in excel. Transition 
probabilities and care costs for Colombia were obtained from a literature review 
and surveillance databases. Oseltamivir effectiveness was meta-analyzed from 
randomized trials and observational studies. Incremental cost-effectiveness ratio 
(ICER) for oseltamivir in the prevention of pneumonia complication in population 
under five years of age and older than 65 year old with ILS was estimated. Monte 
Carlo simulation with 10,000 iterations were used to estimate 95% confidence 
interval. Costs were expressed in 2013 USD. RESULTS: A total of 275,788 ILS cases 
in children and 86,675 in elderly population were estimated for 2014. Whit no 
oseltamivir would occur 75,789 and 62,817 pneumonias in children and elderly, 
respectively, and a total 22,719 deaths. Including the oseltamivir treatment at 
90% coverage would avert 33,462 pneumonias and 6639 pneumonia deaths. The 
oseltamivir cost were estimated on US$ 6,419,552, and it would be a cost-saving 
intervention in population younger than 5 years old and equal or older than 65 
years old with an ICER of US$ -953 (IC95% US$-934 to -759). CONCLUSIONS: The 
use of oseltamivir in children and elderly whit ILS appear to be a cost-saving 
strategy in Colombia, to prevent pneumonia and death complications, when it is 
administrated between 48 hours of symptoms onset.
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OBJECTIVES: To project the cost savings of introducing Fecal Microbiota Transplant 
(FMT) treatment for Clostridium difficile infection (CDI) as compared to current 
practice, by age, and three major subpopulations; hospitals, long-term care facilities 
(LTCF), and communities. METHODS: We modified our existing CDI decision ana-
lytic model to project the total cost savings of FMT as compared to current antibiotic 
treatment for CDI over five years (2015-2019), by integrating current annual trends 
in CDI, and population projections for Canada, by age, gender, and three major sub-
populations. To estimate current annual trends in CDI we conducted a systematic 
analysis of the latest provincial and federal CDI data in Canada. RESULTS: Over the 
next five years, CDI treatment with FMT is estimated to result in a potential cost 
savings of $300.4 M as compared to current practice. We projected 20,700 fewer cases 
of CDI in the FMT treatment arm, due to fewer recurrences for FMT. The recurrence 
rates for current antibiotic treatment were estimated at 25.3% and 35.9% for first 
and second recurrences, respectively. The recurrence rate for FMT was 10.4%. Over 
90% of the cost savings for FMT as compared to antibiotic treatment are for ages 60 
and over, with $127.3 M for ages 60 to 79 years, and $148.3 M for ages 80 and over. By 
subpopulation, over the next five years FMT would result in a potential cost savings 
of $216.5 M for hospital-acquired CDI (HA-CDI), and $68.7 M for community-acquired 
CDI (CA-CDI). CONCLUSIONS: Introducing FMT could result in a substantial cost 
savings over the next five years in Canada. As the Canadian population ages, and 
the numbers of CDI cases among the elderly might grow, FMT holds the promise of 
higher potential cost savings.
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OBJECTIVES: Chronic hepatitis C virus (HCV) incurs significant economic costs to 
the society. There is a paradigm shift in the treatment of hepatitis C with the intro-
duction of sofosbuvir. It is highly efficacious and safe but is an expensive treatment 
alternative to existing treatment options. The study goal is to provide an in-depth 
review of economic studies that have evaluated the cost-effectiveness of sofosbu-
vir in hepatitis C. METHODS: A comprehensive literature search was conducted 
using electronic databases such as PubMed, CINAHL, Scopus, and Cochrane Reviews. 
The search strategy included treatment-naïve as well as treatment-experienced 
patients of all genotypes. Full-text, published articles from Europe and United 
States (U.S.) were identified. Data on decision model, perspective, comparators, 
time horizon, costs, outcomes, price year, sensitivity analysis, and results were 
extracted from the reviewed studies. RESULTS: A total of 9 economic studies (5 
U.S. and 4 Europe) were identified from the literature. The comparators included 
no treatment, peginterferon+ribavirin, boceprevir, telaprevir, and simeprevir based 
regimens. Markov model utilized by all studies to simulate disease progression 
over a lifetime horizon. The cost/QALY for treatment-naïve, patients ranged from 
US$21,869-$31,152 for genotype 1 and US$78,146-$99,189 for genotype 2 and 3. The 
cost/QALY for treatment-experienced patients was US$2,277-$4290 for genotype 1 
and US$55,280-$128,324 for genotype 2 and 3. Overall, sofosbuvir was cost effec-
tive in younger patients and those with severe fibrosis. Sofosbuvir and simeprevir 
combination led to an average cost savings of US$91,590. CONCLUSIONS: Genotype 
1 HCV is the predominant genotype that is generally difficult to treat. Sofosbuvir 
is cost effective for both treatment-naïve and treatment-experienced genotype 1 
patients. For genotypes that are not predominant, decision on the use of sofosbuvir 
should be made based on the willingness-to-pay threshold values. Factors that were 
found to influence cost-effectiveness of sofosbuvir include disease severity, duration 
of treatment, and age of patients.
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with an average patient age of 63.4 (±15.8) years in the SBT group, and 81 residents 
placed 262 CVC catheter lines in patients with an average age of 62.8 (±15.2) years 
in the control group. Compared to the traditional training, the SBT was a dominant 
case with cost-saving (-$5,062, p= 0.002), and reductions of overall complications 
(3.9%, p= 0.017) and severe complications (3%, p= 0.043) per admission, resulted in 
the incremental cost-effectiveness ratios of -$1,298 (= -$5,062/3.9%) and -$1,687 (= 
-$5,062/3.0%) per 1% averted probability of overall and severe complications gained, 
respectively. The total benefit cost ratio was 10.2. Even in the first year, the SBT 
demonstrated a high return on investment (ROI) of 649% with a $4,863 net benefit 
per admission. The ROI could reach 934% and 986% in 5 years and 10 years, respec-
tively. CONCLUSIONS: Using SBT for CVC insertion is a cost-effective approach that 
can be widely implemented.
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OBJECTIVES: The aim of this analysis is to estimate the cost-effectiveness of anid-
ulafungin for the treatment of invasive candidiasis in Colombia. METHODS: We 
constructed a decision tree to determine the incremental cost-effectiveness ratio 
(ICER) of anidulafungin (200 mg on the first day, followed by 100 mg daily) compared 
to amphotericin B deoxycholate (0.7-1.0 mg daily); amphotericin B liposomal (5.0 
mg/ kg daily); caspofungin (70 mg on the first day followed by 50 mg daily) and 
fluconazole (800 mg on the first day followed by 400 mg daily) for the treatment the 
patients with invasive candidiasis. The perspective is that of the Colombian health 
system including only direct costs. All currency units are in USD $ (1 USD$ = COP 
1,971). We used a time horizon of life expectancy. A 5 % discount rate was used. The 
results were measured in quality-adjusted life year (QALY). The efficacy, safety and 
utility data were taken from the literature. Bayesian mixed treatment comparison 
method was applied for the comparison of treatments. The costs of procedures were 
obtained of ISS tariff manual of 2001 and for drugs were used current price regula-
tion and the SISMED database. Univariate and probabilistic sensitivity analyses 
were performed. RESULTS: The total expected costs per patient were: anidulafungin 
USD$ 4,685.61; amphotericin B deoxycholate USD$ 928.22; amphotericin B liposomal 
USD$ 25,569.12; caspofungin USD$ 3,368.48; fluconazole USD$ 628.39. The results for 
each alternative in terms of QALY were: anidulafungin 3.08; amphotericin B deoxy-
cholate 2.26; amphotericin B liposomal 1.90; caspofungin 2.14; fluconazole 2.46. 
The ICER per QALY of anidulafungin compared to fluconazole was USD$ 6,521.38. 
Amphotericin B deoxycholate, amphotericin B liposomal and caspofungin were 
dominated alternatives. CONCLUSIONS: Assuming as threshold for Colombia GDP 
per capita USD$ 7,609.42 anidulafungin is a cost-effective alternative for the treat-
ment of the patients with invasive candidiasis.
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OBJECTIVES: To assess the value of linezolid compared with vancomycin in the 
treatment of cSSSIs caused by MRSA from a payer perspective in the Kingdom of 
Saudi Arabia (KSA) using a two week decision analytic model. The model com-
prehensively covers direct medical costs within inpatient and outpatient settings 
related to both treatments. METHODS: Published literature and local expert opin-
ion provided clinical inputs and resource utilization data on MRSA efficacy, failure/
AE rates, length of stay (LOS), at-home parenteral administration, and outpatient 
resource use. Cost data were derived from local sources and expert feedback. 
The base case analysis assumed equal efficacy for treatment comparators within 
the 14 day length of treatment timeframe. Scenario-based sensitivity analyses 
were conducted by varying LOS data, using unit LOS costs from World Health 
Organization website, and excluding peripherally inserted central catheter (PICC) 
costs. RESULTS: The base case analysis resembled a cost-minimization analysis 
due to an equal efficacy assumption. Total drug acquisition costs were lower for 
vancomycin compared to linezolid (SAR1,885 vs. SAR7,641 respectively). However, 
the overall cost of treatment including drugs, clinical failures, complications, and 
outpatient parenteral administration were lower with linezolid (SAR14,246) than 
with vancomycin (SAR15,804) resulting in substantial cost-savings of SAR1,558 
vs. vancomycin. Linezolid provided savings due to lower outpatient medical costs 
(SAR1,548 vs. SAR7,831), specifically from outpatient parenteral administration. 
These findings were reinforced in all of the scenario sensitivity analyses, and 
linezolid was consistently the cost saving treatment alternative. CONCLUSIONS: 
Results from this analysis demonstrate the overall economic savings resulting 
from linezolid use compared with vancomycin for the treatment of MRSA cSSSI. 
Savings are seen primarily in the outpatient settings because linezolid has an oral 
formulation and does not require outpatient parenteral administration compared 
to other intravenous antibiotics.
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OBJECTIVES: Influenza disease may result in a severe disease causing hospitaliza-
tion and deaths in younger children and older adults. Early antiviral treatment 
may improve clinical outcomes. Our goal was to estimate the oseltamivir cost-
